Bill > H3223

This bill aims to promote transparency in prescription drug prices. It has the following key provisions: 1. The Health Policy Commission and the Center for Health Information and Analysis will identify up to 15 prescription drugs each year that have experienced significant price increases, and this information will be provided to the Office of the Attorney General. 2. The Attorney General will require the manufacturers of these identified drugs to justify the price increases and provide relevant information and supporting documentation. The Attorney General will then report this information to the Legislature and the public. 3. Manufacturers will be required to report to the Health Policy Commission any planned price increases of 10% or more over a 12-month period or the introduction of a new drug that may impact the state's cost benchmark. The report must include detailed information about the drug, such as research and development costs, marketing expenses, and the manufacturer's overall financial information. 4. The bill also requires the Health Policy Commission to hold annual public hearings to examine health care costs, including prescription drug costs, and to report on strategies to increase the efficiency of the health care system. The overall goal of the bill is to increase transparency around prescription drug pricing and costs, which may help policymakers and the public better understand and address the drivers of rising health care expenditures in the state.

Health and Social Services

https://malegislature.gov/Bills/190/H3223